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Background: The insulin receptor (IR) regulates glucose homeostasis, cell growth and differentiation. It has been
hypothesized that the specific signaling characteristics of IR are in part determined by ligand-receptor complexes
localization. Downstream signaling could be triggered from the plasma membrane or from endosomes. Regulation
of activated receptor's internalization has been proposed as the mechanism responsible for the differential isoform
and ligand-specific signaling.
Results: We generated a traceable IR chimera that allows the labeling of the receptor at the cell surface. This
mutant binds insulin but fails to get activated and internalized. However, the mutant heterodimerizes with wild
type IR inhibiting its auto-phosphorylation and blocking its internalization. IR membrane retention attenuates AP-1
transcriptional activation favoring Akt activation.
Conclusions: These results suggest that the mutant acts as a selective dominant negative blocking IR
internalization-mediated signaling.
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Insulin receptor (IR) is a tetrameric tyrosine kinase re-
ceptor involved on glucose homeostasis, cell growth and
differentiation. Two IR variants are produced in mam-
mals by alternative splicing: IR-A lacking exon 11 and
the full length IR-B [1,2]. While IR-B is widely expressed
in adult tissues, embryos predominantly express IR-A
where it functions as a regulator of cellular proliferation
and differentiation [3]. Alterations in the ratio of IR iso-
form expression have been associated with cellular
dysregulation and disease. Some reports showed that in
diabetic patients there are differences at the mRNA level
in the IR-A/IR-B ratio in skeletal muscle [4,5], however
this was not observed by others [6-8]. Cancer cells com-
monly express the IR-A subtype [9-12]. In addition,
there are differences in the activation and signaling* Correspondence: federico@fbmc.fcen.uba.ar
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reproduction in any medium, provided the orevents between the two isoforms, indicating specific
functions [13-15]. Using an elegant harmonic oscillator
mathematical model, Knudson et al. reported that insu-
lin has 1.5-fold higher affinity and a 2-fold higher dis-
sociation rate for IR-A, than for IR-B [16]. On the other
hand, IR-B binds insulin with higher affinity than for in-
sulin like growth factor II (IGF-II) [3]. Additionally, it
has been recently shown that IR-A binds IGF-II with a
lower affinity than insulin [17], in contrast with a previous
report informing similar affinities [3]. Over-expression of
IR-A was suggested to contribute to the modulation of in-
sulin and IGF responses in different tissues and during
cancer progression [18]. Hybrid receptors are formed in
cells where IR and IGF-I receptor (IGF-IR) are co-
expressed and this is common in tumor tissues. Thus, the
relative expression levels of IR-A, IR-B and IGF-IR affect
sensitivity to ligands (IGF-I, IGF-II, insulin).
The link between metabolic and mitogenic effects of in-
sulin are clinically relevant since, for instance, insulin
treated type 2 diabetics are more likely to develop tumors
[19]. Furthermore, their cancer risk may be modified by
different treatments [20,21] and modified insulin ana-
logues with distinct receptor-binding characteristics
showed different mitogenic potencies in cell lines andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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analogues with lower dissociation constant from the IR [24].
Binding of insulin to the IR leads to its kinase activation,
promoting the phosphorylation in cis and trans of tyrosine
residues. Phosphorylated IR activates downstream cas-
cades affecting glucose uptake, metabolism, cell growth,
differentiation, gene expression and cell cycle progression.
It has been postulated that the balance between these ef-
fects is affected by the receptor localization and redistribu-
tion. Activated ligand-receptor complexes are internalized
into endosomes where the IR kinase would be able to
phosphorylate substrates that are spatially distinct from
those accessible at the plasma membrane affecting the bal-
ance between metabolic and mitogenic response. At the
cell membrane activated IR recruits IRS-1 and Akt leading
to the translocation of the glucose transporter and the ac-
tivation of the metabolic response [25]. On the other
hand, endosomes have long been proposed as signaling
platforms [26], and activated IR internalization is required
for the activation of the Shc/MAPK leading to the activa-
tion of early response genes and the activation of the acti-
vating protein transcription factors (AP-1), a hallmark of
the mitogenic response [27-29].
Here we describe an IR-B chimera that can be modi-
fied exclusively at the plasma membrane by inserting
three copies in tandem of the A1 tag [30] in the second
Fibronectin type III domain (FnIII-2) of IR-B. This
chimera binds insulin but fails to be activated or inter-
nalized. We show that it acts as a selective dominant
negative IR by retaining the activated receptor at the
plasma membrane, blocking AP-1 induction but main-
taining Akt activation.
Results and discussion
Recently we studied insulin and IGF-II endocytosis dy-
namics in living cells through IR-B [31,32]. Here we report
novel IR-B chimeras containing an extracellular tag suit-
able to be covalently modified at the plasma membrane.
The tag, cloned into the IR-B sequence, is specifically rec-
ognized by the acyl carrier protein (ACP) syntase (ACP-S)
which transfers a 4’-phosphopantetheine group from the
Coenzyme A (CoA) to a conserved serine inside the A1
sequence. This approach allowed us to label IR-B with
small fluorescent dyes or biotin exclusively at the plasma
membrane and the modification showed no effect on insu-
lin binding. These chimeras bind insulin but fail to be acti-
vated being retained at the cell surface. Co-expression
with wild type IR showed that these mutants function as
selective dominant negatives inhibiting the induction of
AP-1 activity by insulin without affecting Akt activation.
Imaging of IR exclusively at the plasma membrane
We generated the plasmids pcDNA3-IR-B-A1×3 (Mut)
and pcDNA3-IR-B-A1×3-GFP (Mut-GFP) by fusing theA1 tag (GDSLDMLEWSLM) [30] three times in tandem
into the IR-B at the position 626 of the amino acids se-
quence (exon 9). This position is localized on the FnIII-2
domain of IR-B (Figure 1A), and does not contain
known residues involved in pathological mutations,
glycosilations sites, or cysteines which are important in
post-transductional modifications. We hypothesize that
this position does not affect insulin binding since it is lo-
cated inside a domain that is not involved in the ligand-
receptor ligand contact [33,34]. Other chimeras tagged
on the first large Leucine rich domain (L1) showed cor-
rect expression but failed to bind insulin (unpublished
data). The new chimeras allowed us to label the IR
extracellular portion in living cells following the protocol
showed in Figure 1B. Cells expressing the tagged IR
mutants were labeled using ACP-S which transfers a 4’-
phosphopantetheine group from the CoA to the A1 se-
quence (in red, Figure 1A). When the membrane
impermeable CoA is covalently bound to a fluorescent
or a biotinylated group by the sulfhydryl extreme this
modification is transferred to the tagged protein ex-
posed to the extracellular medium.
Living HeLa cells expressing the chimeras (Figure 1C-E)
were labeled with 0.2 μM ACP-S and 1 μM CoA conju-
gated with the fluorescent ATTO-532 (CoA-532) or
CoA-550. Both mutants localize correctly at the plasma
membrane. Co-localization between green fluorescent
protein (GFP) and CoA-550 signals was evaluated by
Manders analysis: CoA-550 associated pixels were local-
ized to the plasma membrane and co-localized with GFP
signal (Figure 1E). Western blot experiments showed the
correct molecular weight and similar levels of expression
than wild type IR-B (Figure 1F). It should be noted that
expression levels of endogenous IR in HeLa cells are bel-
low the detection threshold of our experimental approach
as we have previously reported [32].
Tagged IR-B binds insulin but fails to be activated
Next, we studied the ability of the tagged receptors to
bind insulin. Cells were incubated with 50 nM biotin
amido caproyl insulin (BAC-Ins) for 15 min and then
with 1 nM streptavidin (SA) conjugated quantum dots
(QD) 655 (QD655) (maximum emission pick: 655 nm)
for 10 min at room temperature [30]. QD incubation
was performed with or without previous ACP labeling
(Figure 2). Cells expressing Mut-GFP showed insulin
binding with or without ACP labeling (Figure 2A-D).
Similarly, insulin binding was observed in cells express-
ing Mut previously labeled with CoA-488 (Figure 2E).
Binding have shown to be specific since non-transfected
cells did not show QD655 signal (non-transfected cells
at the same observation field and data not shown).
Activation of the tagged IR in response to insulin
was analyzed by immunofluorescence using a specific
Figure 1 Covalent modification of IR-B at the plasma membrane. A. Tag position and insulin binding scheme according to proposed model
[33,34]. L1, Large leucine rich domain 1; CR, cysteine rich domain; L2, large leucine rich domain 2; FnIII domains 1, 2 and 3; ID, inter-domain; TM,
transmembrane domain; TK, tyrosine kinase; CT, C-terminus. Inserted tag shows: in grey, residues added for cloning reasons; in red, Ser
recognized by ACP-S; in blue, conserved flanking amino acids for enzyme recognition [30]. B. Labeling strategy. C-E. HeLa cells expressing Mut-
GFP (C-D) or Mut (E) were labeled with 0.2 μM ACP-S and 1 μM fluorescent CoA and imaged by confocal (Mut-GFP) or wide field microscopy
(Mut). Scale bars: 10 μm. D. Manders map. F. Cells transiently expressing wild type IR-B or the mutant were assayed by Western blot 48 h after
transfection using anti-IR-β-subunit or anti-ERK1/2. Quantification was performed by densitometry. Results are expressed as the mean ± s.e.m.
(*: p≤0.05; n≥3).
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Figure 2 Insulin binding assays. A. Strategy for insulin binding and QD655 labeling. B. HeLa cells expressing Mut-GFP were incubated with 50
nM BAC-Ins and 1 nM QD655, fixed and imaged by confocal microscopy. C. Insulin binging after ACP labeling. D-E. Cells expressing the mutants
were labeled with 0.2 μM ACP-S and 1 μM fluorescent CoA and then with 50 nM BAC-Ins and 1 nM QD655. Imaging was performed by confocal
(D) or wide field microscopy (E). Scale bars: 10 μm.
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Western blot using an anti-phospho-tyrosine (pY20) anti-
body. While IR-B and IR-B fused to the super cyan fluor-
escent protein (SCFP) (IR-B-SCFP) could be activated
after 10 min by recombinant human insulin (rhIns), both
mutants did not show any activation signal (Figure 3). Ac-
tivation in cells transfected with IR-B or IR-B-VFP was de-
tectable by immunofluorescence and Western blot. By
contrast, non-transfected cells (see cells without GFP sig-
nal in Figure 3C) or cells transfected with the empty vec-
tor [31] did not show detectable levels of activation.
Activation of Mut-GFP was also analyzed after 5 or 15
min of rhIns stimulation and no activation was detected
(Additional file 1: Figure S1).
Insulin binding leads to the phosphorylation of IR trig-
gering different signaling pathways. However, IR signalingis not limited to its activation at the membrane. Activated
ligand-receptor complexes are internalized into endo-
somes where the IR kinase would be able to phosphorylate
substrates that are spatially distinct from those accessible
at the plasma membrane. Therefore, we studied the endo-
cytosis of the tagged IR after insulin binding ACP-S acts
optimally at 37°C and at this condition receptors could be
recycled or internalized. We tested two different labeling
temperatures (15°C and room temperature) finding that
room temperature allowed both ACP and QD labeling
with undetected internalization (Additional file 2: Figure
S2A). Cells expressing Mut were labeled at room
temperature with BAC-Ins and QD655, incubated at 37°C
and directly fixed or acid treated to remove the ligand
bound to the IR at the cell surface [31,32,35]. After acid
treatment no QD655 signal was detected inside the cells
Figure 3 Chimeras characterization. A. HeLa cells expressing Mut-GFP (A), Mut (B), IR-B-SCFP (C) or IR-B (D) were stimulated with 100 nM rhIns
for 10 min and fixed. Immunofluorescence assays were performed with anti-phospho-IR and a secondary antibody conjugated with Alexa fluor
555. Cells expressing Mut were labeled with 0.2 μM ACP-S and 1 μM CoA-488 before stimulation. E. Cells expressing wt IR-B or the mutant were
stimulated with 100 nM rhIns for 5 min and lysates were analyzed by Western blot using anti-pY20 and anti-IR-β subunit. Quantification was
performed by densitometry. The ratio pY20 / IR was measured for each lane and fold induction was calculated with respect to basal levels.
Results are expressed as the mean ± s.e.m. (*: p=0.002; n≥3). ´p´ means phospho-antibodies.
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cytosis was blocked. In contrast, cells expressing wt IR-B
showed normal endocytosis (Figure 4B) [30].
Mut dimerizes with functional IR at the plasma
membrane and blocks its internalization
We biotinylated the IR in cells co-expressing IR-B-SCFP
and Mut and performed a SA-pull down assay followed
by Western blot to confirm the presence of IR-B/Mut
dimers at the plasma membrane. Transfected cells were
incubated with 2 μM ACP-S and 1 μM CoA-biotin and
correct surface modification was observed by labeling
cells with 1 nM SA-550. The modification was specific
and only present at the surface (Additional file 2: Figure
S2B). The presence of IR-B-SCFP in the pull down frac-
tion indicates that Mut was able to dimerize with wild
type receptors (Figure 5A). Densitometric and statistical
analysis showed that dimerization occurred stochastic-
ally without differences between mutant or wild type re-
ceptors (Additional file 3: Supplemental Experimental
Procedures).To analyze Mut's effect on insulin signaling we first eval-
uated IR phosphorylation in cells co-expressing IR-B and
increasing amounts of Mut. Western blot experiments
showed that IR phosphorylation was reduced by Mut in a
concentration dependent manner (Figure 5B) suggesting a
dominant negative effect.
Cells co-expressing Mut and wild type IR-B showed that
Mut blocks insulin-IR complex endocytosis (Figure 5C).
Cells with high levels of mutant expression (revealed by
CoA-488 signal) showed a low proportion of internalized
BAC-Ins-QD655 compared with cells with a low expres-
sion where a high endocytosis degree was observed. We
quantified the QD655 signal inside the cell, at the mem-
brane and the percentage of internalized QD (Additional
file 4: Figure S3). The mutant's effect on internalization
was analyzed in cells co-expressing IR-B with similar ex-
pression levels (CoA-488>1600 cts). While IR-B is inter-
nalized (49±5%; n=14), the mutant does not (7±2%; n=6)
and retained IR-B at the membrane (18±2%; n=32) when
they are co-expressed (Figure 5D). We further confirmed
that no internalization took place at later time points (15,
Figure 4 Mutant retention at the plasma membrane. A. HeLa cells expressing Mut labeled with 0.2 μM ACP-S and 1 μM CoA-488 were
incubated with 50 nM BAC-Ins and 1 nM QD655. Cells were fixed or acid treated before fixation. Right panel: cells were incubated at 37°C for 30
min and fixed with or without acid treatment. B. Cells expressing IR-B were labeled with 50 nM BAC-Ins and 1 nM QD655, incubated or not at
37°C for 30 min and fixed or previously acid treated. Samples were imaged by confocal microscopy. Scale bars: 10 μm.
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IR-B and IR-B-VFP showed almost complete insulin in-
ternalization after 150 min [31,32].
The IR phosphorylation pattern regulates its internal-
ization and is the proposed mechanism for the diver-
gence of the mitogenic and metabolic signaling. It was
postulated that its kinase activity modulation leads to
the differential balance between metabolic and mitogenic
response [36].
Mut blocks insulin induced AP-1 activity without affecting
Akt activation
To test the effect of the membrane retention down-
stream the IR, we measured AP-1 transcriptional activity
induced by insulin using a luciferase reporter assay. Cells
co-expressing AP-1-Luc, IR-B and increasing amounts
of Mut were stimulated with 100 nM rhIns for 16 h. AP-
1 induction was significantly decreased by Mut in a con-
centration dependent manner (Figure 6A). To further
analyze this effect on endogenous IR, we measured AP-1
activity in response to insulin in HEK293 cells, which
express predominantly IR-A. Increasing amounts of Mutsignificantly reduced insulin induction of AP-1 activity
(0.1 μg DNA: 44% of reduction; 0.2 μg DNA: 92% of re-
duction) (Figure 6A). These results indicate that Mut-IR
acts as a dominant negative in the pathway leading to
AP-1 activation.
It is known that Akt translocates to the plasma mem-
brane where interacts with the kinases that induce its ac-
tivation to regulate glucose metabolism, differentiation,
protein synthesis and cell survival and proliferation
[37-39]. We confirmed Akt recruitment to the membrane
after insulin activation by quantitative immunofluores-
cence. Cells co-expressing IR-B-SCFP and Akt-HA (Akt
fused to the human influenza hemagglutinin tag, HA)
were stimulated with rhIns and the proportion of Akt at
the membrane was quantified. As expected, Akt trans-
located to the plasma membrane in response to insulin
(control: 90±0.5%; rhIns: 160±0.9%; n=34-40 cells; p<10-5)
(Figure 6B). Expression of the mutant alone or together
with IR-B-SCFP did not change the intracellular re-
distribution of Akt after insulin stimulation (Figure 6C).
Moreover, Western blot experiments showed that expres-
sion of the mutant increased Akt activation in a
Figure 5 Dimers wild type / mutant at the plasma membrane and signaling. A. HeLa cells expressing Mut, IR-B-SCFP or both were treated
with 2 μM ACP-S and 5 μM CoA-biotin for 30 min. Lysates were incubated with SA-agarose beads for 1 h at 4°C. Precipitates and total fractions
were analyzed by Western blot with anti-IR-β subunit. B. HeLa cells were co-transfected with 0.1 μg pcDNA3-IR-B and different amounts of the
mutant or EV, stimulated with 100 nM rhIns for 5 min and assayed by Western blot. Quantification was performed by densitometry measuring
pY20 signal with respect to the first lane (basal) (*: p<0.05, n=4). C. HeLa cells co-expressing Mut and IR-B were labeled with 2 μM ACP-S and 2
μM CoA-488 and then incubated with 50 nM BAC-Ins and 1 nM QD655. Cells were directly fixed or incubated for 30 min at 37°C and then fixed
or acid treated before fixation. Samples were imaged by confocal microscopy. Scale bars: 10 μm. D. Internalization analysis. Results are expressed
as the mean ± s.e.m (p<0.005; n=6-32 cells).
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is not observed for ERK1/2 activation (Additional file 6:
Figure S5).
There are at least seven tyrosines subjected to phos-
phorylation upon insulin binding [40]: Tyr965 and
Tyr972 are phosphorylated in cis and involved in sub-
strates selection [41]; Tyr1328 and Tyr1334 play a key
role in mitogenic signaling and are not involved in me-
tabolism and Akt signaling [42,43]; Tyr1158, Tyr1162
and Tyr1163 are the first residues to be phosphorylated
in trans, known to mediate kinase activation and intern-
alization [44]. It has been postulated that the degree of
IR kinase activation leads to the differential balance be-
tween metabolic and mitogenic response [36]. IR intern-
alization is required for Shc/MAPK pathway activation
but not for IRS-1 and Akt phosphorylation suggesting
that these molecules could be activated at the mem-
brane [37-39,45-47]. We hypothesize that the mutant,
acting both in cis or trans, could be affecting the phos-
phorylation pattern of the hertero- and homo-dimers
blocking IR internalization and favoring membrane
signaling.
Conclusions
These results suggest that the mutant is acting as a
selective dominant negative, blocking internalization
and signaling from endosomes without affecting Aktactivation at the cell surface. Our results are in agree-
ment with the model proposing that the internaliza-
tion dynamics is crucial for specific IR signaling suggested
from different independent studies and reviewed by
Jensen and De Meyts [47]. The mutant binds insulin but
fails to get activated. When this chimera dimerizes with
wild type IR, hybrid receptors fail to get fully phosphory-
lated and are consequently retained at the plasma mem-
brane, promoting Akt activation and inhibiting endosomal
signaling.
Methods
Materials
rhIns was provided by Laboratorios Beta (Argentina).
BAC-Ins was from Sigma (Germany). Mouse monoclonal
anti-IR-β subunit, rabbit monoclonal anti-phospho-Akt
(Ser473), anti-Akt, anti-ERK1/2 and anti-phospho-IR-β
subunit (Tyr1361) were from Cell Signaling Technology
(Beverly, MA). Mouse monoclonal anti- pY20 was from
BD Transduction Laboratories (San Jose, CA). Mouse
monoclonal anti-PY99 was from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). QD655 and secondary antibodies
conjugated with Alexa fluor 555 were from Molecular
Probes, Invitrogen (Eugene, OR). Lipofectamine Reagent
2000 was from Invitrogen (Carlsbad, CA). Buffers and
enzymes for cloning were from New England Biolabs
(Ipswich, UK), Promega (Madison, WI) and Invitrogen
Figure 6 Mutant IR blocks insulin induced AP-1 activity without affecting Akt activation. A. HeLa or HEK293 cells co-expressing AP1-Luc,
IR-B and different amounts of the mutant were starved for 24 h and then stimulated with 100 nM rhIns for 16 h. Luciferase activity was measured
and fold induction was calculated (*: p≤0.03, **: p=0.003; n≥3). B. Akt translocation to the plasma membrane: HeLa cells co-expressing IR-B-SCFP
and Akt-HA were starved overnight and then stimulated with 100 nM rhIns for 5 min. After fixation samples were stained with anti-Akt and a
secondary antibody conjugated with Alexa fluor 555. Images were acquired by confocal microscopy and quantification of Akt re-distribution was
evidenced (*: p<10-6; n=34-40 cells). Scale bars: 10 μm. C. Similar experiment was performed using anti-phospho-Akt in cells co-expressing Akt-HA
with: i) IR-B-SCFP, ii) Mut iii) both (n=15-23 cells). D. Cells co-transfected with 0.1 μg pcDNA3-IR-B and different amounts of the mutant or EV were
stimulated with 100 nM rhIns for 5 min and assayed by Western blot. Quantification was performed by densitometry measuring phospho-Akt
signal normalized to the first lane (basal) (*: p<0.05, n≥3). ´p´ means phospho-antibodies. Results are expressed as the mean ± s.e.m.
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(Valencia, CA). The plasmid containing luciferase re-
porter gene downstream of 7 binding sites for AP-1
(p-AP-1-Luc) and Akt-HA were generously providedby Dr Omar Coso and Dr Anabella Srebrow (IFIBYNE,
Argentina) respectively. The plasmids pcDNA3-IR-B,
pcDNA3-IR-B-GFP and pcDNA3-IR-B-SCFP were re-
cently described [31,32].
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pcDNA3-IR-B-A1×3-GFP (Mut-GFP): oligonucleotides
with the A1 sequence (A1BamHI5’: 5´-gatcttggtgactctctgg
acatgctggagtggagtctgatgggt-3´; A1BamHI3’: 5´-gatcacccatc
agactccactccagcatgtccagagagtcaccaa-3´) were annealed for
5 min at 100°C cooling it to RT (500 mM NaCl, 10 mM
EDTA, 100 mM Tris–HCl pH 7.5). Presence of double
strand DNA with sticky ends for BamHI was tested by an
absorption spectrum. Annealing product was treated with
T4 PNK. The pcDNA3-IR-B-GFP was digested with
BamHI restriction enzyme and ligated with the A1 tag
with the BamHI ends. pcDNA3-IR-B-A1×3 (Mut): Mut-
GFP was digested with NheI and ApaI restriction en-
zymes, treated with Klenow and T4 DNA polymerase and
then re-ligated to generate Mut.Cell culture and transfections
HeLa cells were maintained in DMEN (GIBCO; Grand
Island, NE) supplemented with 100 U/ml penicillin,
100 μg/ml streptomycin and 10% fetal bovine serum
(FBS) at 37°C in 5% CO2. HEK293 cells were similarly
maintained adding 1 mM sodium pyruvate. Cells were
plated at 1×105 cells/well density in 24 well plates (lucifer-
ase assays) or onto 12 mm glass coverslips (microscopy)
or at 2.5×105 cells/well density in 12 wells plates (Western
blot) one day before transfection in DMEM/10% FBS.
Cells were transfected with Lipofectamine Reagent 2000
according to manufacturer protocols.Western blots
Following stimulation with 100 nM rhIns cells were lysed
in 100 mM Tris–HCl pH 6.8, 4% SDS, 0.2% Bromophenol
blue, 20% glycerol, 200 mM β-mercaptoethanol, vortexed
for 20 sec and boiled for 5 min. After 10% SDS-PAGE and
transfer, PDVF membranes were blocked in 5% non-fat
dried milk in 0.1% Tween-TBS buffer (TTBS) for 1 h,
washed and incubated overnight at 4°C with primary anti-
bodies diluted in 5% BSA/TTBS. The following day, mem-
branes were incubated with secondary antibodies for 1 h
and developed by chemiluminescence. Quantification was
performed by densitometry using ImageJ plugins (NIH).Luciferase reporter assay
Cells seeded onto 24 well plates the day before were
transfected using 0.3 μg pcDNA3-IR-B (HeLa cells) or
EV (HEK293 cells), 0.05 μg pAP-1-Luc and different
amounts of Mut. After 24 h, cells were starved one day,
and then stimulated for 16 h with 100 nM rhIns. Lucif-
erase activity was determined using Luciferase Reactive
and Reporter Lysis Buffer from Promega (Madison, WI)
and normalization to the control (non-stimulated cells)
was performed.Expression and purification of ACP-S
Protein expression
TOP 10 Ecoli cells (araBADC- and araEFGH+) were
electroporated with pBAD-ACPwt-S plasmid (provided
by T.M. Jovin and D.J. Arndt-Jovin, Max Planck Institute
for Biophysical Chemistry, Germany), plated on Luria
Broth agar and incubated at 37°C overnight. The next
day, a 2×YT starting culture was inoculated overnight at
37°C. We diluted (1/200) the starting culture and growth
it at 37°C to an optical density of 0.8. The expression
was induced with 0.1% (w/v) L-(+)-arabinose (SIGMA-
Aldrich, Germany)and incubation at 30°C overnight and
the next day cells were harvested. The pellet was
resuspended (10 ml/g pellet) in Lysis Buffer (80 mM
imidazole pH 8.0, 250 mM NaCl and protease inhibitor)
and was sonicated 3×15 sec. Then 1% Triton X-100 was
added and the suspension was stirred for 15 min at 4°C.
Lysates were centrifuged at 9,500 r.p.m. for 30 min at 4°C
collecting the supernatant.Protein purification by Ni-NTA chromatography
The cleared lysate was incubated with Ni-NTA resin
(20 ml resin per 500 ml lysate) at 4°C for 1 h with stirring.
The resin was then loaded in a 10 ml syringe, washed with
Wash Buffer 1 (500 mM NaCl, 100 mM imidazole pH 8.0)
and then with Wash Buffer 2 (100 mM NaCl, 100 mM
imidazole pH 8.0, 20% glycerol). Elution was performed
with 100mM NaCl, 400 mM imidazole pH 8.0, 20% gly-
cerol. Fractions were analyzed by SDS-PAGE and by
measuring absorption at 280 nm. Fractions containing the
protein were combined and stored at −80°C with 1 mM
DTTafter shock-freezing in liquid nitrogen.CoA derivatives synthesis
CoA-biotin
CoA trilithium salt (FLUKA, St Louis, MO) (1 equivalent)
was dissolved in 50 mM Tris–HCl pH 7.5 by adding 10
volumes of dimethyl sulfoxide (DMSO). This solution was
combined with Biotin-Peo2-maleimide (Pierce, Rockford,
IL) (1 equivalent) dissolved in DMSO at room tempera-
ture for 4 h. Product reaction was purified by Fast protein
liquid chromatography (ÄKTA Purifier 100, GE Health-
care Life Science) with a reverse phase column C18
Kromasil MZ refill 100 (150 mm × 4 mm). Elution was
performed with a gradient acetonitrile: water/0.1%
trifluoroacetic acid from 0:100 to 60:40 in 45 min. The
purified product was characterized by Matrix-Assisted
Laser Desorption/Ionization using a time of flight ion de-
tector (CEQUIBIEM, FCEN-UBA, Argentina) with matrix
3-hidroxipicolinic acid. Quantification was performed by
spectrophotometry (εadenine260nm=15,300 M
-1cm-1). The
product was lyophilised, resuspended in DMSO and
stored at −20°C.
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ATTO-maleimide (488, 532, 550) (ATTO Tec GmbH,
Germany) (2 equivalents) was dissolved in DMSO and
CoA trilithium salt (1 equivalent) was dissolved in MES
(2-(N-morpholino) ethanesulfonic acid) buffer pH 7.0
and one volume of DMSO. We combined both solutions
at 20°C overnight. The product was purified by HPLC
with a reverse phase column C18 Kromasil MZ semi-
prep 100 (250 mm × 8 mm) and the following elution
gradient: (i) 2 min ammonium acetate: acetonitrile
(97:3); (ii) 20 min from 97:3 to 40:60; (iii) 5 min from
40:60 to 0:100. The product identity was confirmed
by mass spectrometry, spectrophotometry and by la-
beling cells expressing A1 tag with ACP-S. Fluores-
cent CoA was lyophilized, resuspended in DMSO and
stored at −20°C.
Label in vivo with ACP-S and CoA derivatives
Transfected cells were washed with Tyrode´s buffer
(135 mM NaCl, 10 mM KCl, 10 mM MgCl2, 1mM
CaCl2, 10 mM HEPES pH 7.2, 0.1% BSA) and incu-
bated with 0.2 or 2.0 μM ACP-S and 1 μM CoA deriv-
atives for 30 min at room temperature and finally
washed four times with Tyrode´s CoA-biotin modifica-
tion was followed by a labeling step with 1 nM SA-
atto550 for 15 min at room temperature. Then cells
were fixed in cold methanol for 30 min at −20°C and
mounted for imaging.
Labeling in vivo with QD655 and BAC-Ins and
internalization
Before the experiment cells were starved overnight and
then incubated with 50 nM BAC-Ins for 15 min at room
temperature, washed and incubated with 1 nM QD655
for 10 min, washed and either fixed in 37% paraformal-
dehyde (PFA) on ice for 20 min or incubated at 37°C in
DMEM for different periods before fixation. When acid
treatment was applied, cells were incubated for 5 min at
room temperature with acid solution (0.1 M Na-glycine
pH 3.0, 0.5 M NaCl) [28-30] and then fixed Imaging was
performed in PBS.
Immunofluorescence
After overnight starvation, transfected cells were stimu-
lated with 100 nM rhIns for 5, 10 or 15 min, washed
with cold PBS and immediately fixed in cold methanol
for 30 min at −20°C, blocked with PBS/0.3% Triton X-100/
1% BSA for 1 h at 37°C and incubated with anti-phospho-
IR-β subunit (0.3 μg/ml), anti-PY99 (1 μg/ml), anti-Akt
(1/400) or anti-phospho-Akt (1/200) overnight at 4°C.
The following day samples were incubated with a second-
ary antibody conjugated with Alexa fluor 555 or Cy3 for
1 h at 37°C, washed and mounted for imaging.Microscopy
Confocal microscopes were Olympus Fluoview FV1000
with a UPLSAPO 60×1.2 N.A. water immersion object-
ive or Zeiss LSM510 Meta with a C-Apochromat 63×1.2
N.A. water immersion objective or a Plan-Apochromat
63×1.4 N.A. oil immersion objective. Excitation and emis-
sion filters were as follows:
SCFP and Alexa fluor 555: Excitation: SCFP, 405 nm;
Alexa fluor 555, 543 nm. Emission: SCFP, band-pass
(BP): 430–470 nm; Alexa fluor 555, BP: 560–620 nm.
CoA-488 and QD655: Excitation: CoA-488, 488 nm;
QD655, 405 nm. Emission: CoA-488, BP: 505–525 nm;
QD655, BP: 640–670 nm.
GFP and Alexa fluor 555: Excitation: GFP, 488 nm;
Alexa fluor 555, 543 nm. Emission: GFP, BP: 505–525 nm;
Alexa fluor 555, BP: 560–620 nm.
CoA-488 and Alexa fluor 555: Excitation: CoA-488,
488 nm; Alexa fluor 555, 543 nm. Emission: CoA-488,
BP: 505–525 nm; Alexa fluor 555, BP: 560–620 nm.
GFP and CoA-532: Excitation: GFP, 488 nm; CoA-532,
532 nm. Emission: GFP, BP: 500/20 nm; CoA-532,
563–606 nm.
GFP, CoA-532 and QD655: Excitation: GFP, 488 nm;
CoA-532, 532 nm; QD655, 488 nm. Emission: GFP, BP:
500/20 nm; CoA-532, BP: 565–615 nm; QD655, long-
pass: 650 nm.
Wide field microscope was Olympus IX71 with a 40×
1.15 N.A. water immersion objective, a mercury arc
lamp excitation, suitable filters and a camera Hamamatsu
Orca CCD C4742-95.
Image processing
Confocal images were processed with Matlab and
ImageJ. Background was subtracted and in some cases a
median filter was applied only for presentation.
Internalization analysis
Segmentation (membrane-interior)
Channel background (median) was subtracted. Cell seg-
mentation was performed manually and pre-membrane
was defined as the difference image of the cell and binary
erosion (iterations: 5–20; alternating connectivity). The
pre-interior was defined as the difference between cell and
pre-membrane. With a mask marking red pixels (QD655)
membrane was defined as the product mask × pre-mem-
brane, and interior as the product mask × pre-interior.
Endocytosis estimation
Values in membrane and interior were summed for both
channel, also sizes were measured In order to compute
the relative amount of internalized red fluorescence we
estimated QDtotal (QDmembrane+QDinterior) and calculated
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levels were estimated as the mean of the CoA-488 signal
(sum of CoA-488/cell size). Cells with similar CoA-488
level were considered.
Quantification of Akt distribution
Each cell was segmentated similarly using SCFP signal,
red signal was measured in each region and Aktmembrane/
Akttotal ratio was calculated.
Pull down experiments
Cells expressing the mutant alone or in combination
with IR-B-SCFP were growth on six well plates. Cells
were incubated with 2 μM ACP-S and 5 μM CoA-biotin
for 30 min at room temperature and after 4 washes with
PBS were lysed (50 mM Tris–HCl pH 7.5, 1 mM EDTA,
1 mM EGTA, 150 mM NaCl, 1% NP40, 1 mM MgCl2,
0.1% SDS, proteases inhibitors). Lysates were incubated
with SA-agarose beads for 1 h at 4°C and centrifuged for
1 min. Supernatants were discarded and beads were
washed with the same buffer twice. Beads were re-
suspended in loading buffer (100 mM Tris–HCl pH 6.8,
4% SDS, 0.2% bromophenol blue, 20% glycerol, 200 mM
β-mercaptoethanol, 1mM DTT) as well as aliquots of
total fractions (4% total lysate volume). Samples were
boiled for 5 min and analyzed by Western blot.
Statistics
Results were expressed as the mean ± s.e.m. p values
were estimated using Student´s T test (2 tails).
For supplementary methods see Additional file 3.
Additional files
Additional file 1: Figure S1. Mut-GFP is not activated after 15 min of
stimulation. HeLa cells were transfected with Mut-GFP (A) or IR-B-GFP
(B) and after overnight starvation they were stimulated with 100 nM rhIns
for 5 or 15 min and fixed. Immunofluorescence assays were performed
with anti-phospho-tyrosine (P99) and a secondary antibody conjugated
with Cy3. Scale bars: 10 μm.
Additional file 2: Figure S2. Effect of the temperature in the
internalization during labeling and CoA-biotin labeling. A. HeLa cells
expressing IR-B were labeled with BAC-Ins and QD655 at room
temperature or at 15°C, fixed and imaged by confocal microscopy.
Images were quantified as described in experimental section and the
percentage of internalization was calculated. Results are expressed as the
mean ± s.e.m. B. HEK293 cells expressing Mut-GFP were incubated with
1 μM CoA-biotin with or without 2 μM ACP-S and then labeled with
1 nM SA-550. Fixed cells were imaged by wide field microscopy. Scale
bars: 5 μm.
Additional file 3: Supplemental Experimental Procedures.
Additional file 4: Figure S3. Effect of expression level on the
internalization. Quantification of BAC-Ins-QD655 internalization was
performed in cells co-expressing Mut and IR-B after 30 min at 37°C
depending on the fluorescence levels of CoA-488. Cells were classified in
high labeling (CoA-488>1600 cts) and low labeling (CoA-488<900 cts).
Results are expressed as the mean ± s.e.m. (*: p=0.01; n=8 cells).Additional file 5: Figure S4. Mut-GFP endocytosis over time. HeLa cells
expressing Mut-GFP labeled with 0.2 μM ACP-S and 1 μM CoA-532 were
incubated with 50 nM BAC-Ins and 1 nM QD655. Cells were incubated at
37°C for 15, 45 or 150 min and then fixed. Samples were imaged by
confocal microscopy. Scale bars: 10 μm.
Additional file 6: Figure S5. Mut effect on ERK1/2 activation. HeLa cells
co-transfected with 0.1 μg pcDNA3-IR-B and different amounts of the
mutant or EV were stimulated with 100 nM rhIns for 5 min and assayed by
Western blot. Quantification was performed by densitometry measuring
phospho-ERK1/2 signal normalized to the basal (*: p<0.05, n≥3). ´p´ means
phospho-antibodies. Results are expressed as the mean ± s.e.m.
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